Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based Lux Biosciences has started treating patients in a Phase I study with its third product candidate, LX214, a proprietary topical ophthalmic solution containing the next-generation calcineurin inhibitor voclosporin.
Subscribe to our email newsletter
The company is developing LX214 as a potential treatment for keratoconjunctivitis sicca, commonly known as dry eye syndrome, and other chronic inflammatory ocular surface diseases.
Lux has filed for a patent covering LX214 with a priority date in 2007. The primary objective of the Phase I study is to evaluate the safety and tolerability of LX214 when applied topically to the eye of healthy volunteers and subjects with keratoconjunctivitis sicca.
Ulrich Grau, president and CEO of Lux Biosciences, said: We are pleased with the progress of our program for LX214, which we advanced from inception into the clinic in 18 months, in parallel with our LX211 and LX201 Phase III development programs.
Lux Biosciences, is a biotechnology company focused on ophthalmic diseases. The pipe line products of Lux include two phase 3 clinical-stage projects LUVENIQ and LX201. Both the LUMINATE pivotal clinical program for LUVENIQ for the treatment of uveitis, as well as the LUCIDA pivotal clinical program with LX201 for the prevention of corneal transplant rejection were initiated in early 2007 and include sites in North America, Europe and India.